10 Facts About Genentech


Genentech, Inc, is an American biotechnology corporation which became a subsidiary of Roche in 2009.

FactSnippet No. 1,561,119

In March 2009 Roche acquired Genentech by buying shares it didn't already control for approximately $46.

FactSnippet No. 1,561,120

In December 2006, Genentech sold its Porrino, Spain, facility to Lonza and acquired an exclusive right to purchase Lonza's mammalian cell culture manufacturing facility under construction in Singapore.

FactSnippet No. 1,561,121

In June 2007, Genentech began the construction and development of an E coli manufacturing facility, in Singapore, for the worldwide production of Lucentis bulk drug substance.

FactSnippet No. 1,561,122

Genentech is a donor to the Center for Health Care Strategies, a non-governmental organization that lobbies the United States Government on issues related to Medicaid.

FactSnippet No. 1,561,123

Genentech Inc Political Action Committee is a US Federal Political Action Committee, created to "aggregate contributions from members or employees and their families to donate to candidates for federal office".

FactSnippet No. 1,561,124

In November 1999, Genentech agreed to pay the University of California, San Francisco $200 million to settle a nine-year-old patent dispute.

FactSnippet No. 1,561,125

Genentech claimed that they developed Protropin, independently of UCSF.

FactSnippet No. 1,561,126

Protropin, a drug used to treat dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to its position as an industry leader.

FactSnippet No. 1,561,127

In 2009, The New York Times reported that Genentech's talking points on health care reform appeared verbatim in the official statements of several Members of Congress during the national health care reform debate.

FactSnippet No. 1,561,128